fluorodeoxyglucose f18 has been researched along with Foot Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muzaffar, R; Osman, MM; Raslan, O | 1 |
| Lortholary, O | 1 |
| Espinosa, N; Fischer, DR; Hany, TF; Hesselmann, R; Johayem, A; Maquieira, GJ; Strobel, K; von Schulthess, GK; Zanetti, M | 1 |
| Ames, D; Bharija, A; Mantil, J; Pelstring, R; Percy, T; Rehani, B; Scheler, J | 1 |
1 review(s) available for fluorodeoxyglucose f18 and Foot Diseases
| Article | Year |
|---|---|
18F-FDG-avid plantar nodules on true whole-body 18F-FDG PET/CT in cancer patients.
Topics: Fibroma; Fluorodeoxyglucose F18; Foot Diseases; Humans; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
3 other study(ies) available for fluorodeoxyglucose f18 and Foot Diseases
| Article | Year |
|---|---|
[Visceral mycoses].
Topics: Fluorodeoxyglucose F18; Foot Diseases; France; Humans; Immunocompromised Host; Mycetoma; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Urban Population | 2015 |
Therapeutic impact of [(18)F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Foot; Foot Diseases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pain; Pain Management; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Increased F-18 FDG uptake on positron emission tomography/computed tomography imaging caused by plantar fibromatosis.
Topics: Aged; Fibroma; Fluorodeoxyglucose F18; Foot Diseases; Humans; Male; Positron-Emission Tomography; Radiopharmaceuticals; Soft Tissue Neoplasms; Tomography, X-Ray Computed | 2008 |